CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement

CONSORT extension for reporting N-of-1 trials (CENT) 2015 Statement

N-of-1 trials provide a mechanism for making evidence-based treatment decisions for an individual patient. They use key methodological elements of group clinical trials to evaluate treatment effectiveness in a single patient, for situations that cannot always accommodate large-scale trials: rare diseases, comorbid conditions, or in patients using concurrent therapies. Improvement in the reporti...

CONSORT extension for reporting N-of-1 trials (CENT) 2015: Explanation and elaboration.

N-of-1 trials are a useful tool for clinicians who want to determine the effectiveness of a treatment in a particular individual. The reporting of N-of-1 trials has been variable and incomplete, hindering their usefulness in clinical decision making and by future researchers. This document presents the CONSORT (Consolidated Standards of Reporting Trials) extension for N-of-1 trials (CENT 2015)....

P05.50. CONSORT extension for N-of-1 trials (CENT) guidelines

Purpose N-of-1 trials have been used in medicine to generate treatment information when evidence from randomized controlled trials (RCTs) is not available or applicable. Nof-1 study design maintains the methodological safeguards provided by RCTs (blinding, randomization and controls) yet avoids the disadvantages associated with large trials. A standardized method of reporting of N-of1 trials, s...

CONSORT statement: extension to cluster randomised trials.

CONSORT 2010 statement: extension checklist for reporting within person randomised trials

s for within person RCTs should indicate the paired or within person nature of the trial. Table 1⇓ shows the minimum information that should be included in the abstract of a within person trial, in addition to the items recommended for all trials. We were not able to find examples of good reporting that tackled all the items required. We therefore developed an example abstract by enhancing a pu...